Have you experienced a decrease in your sexual desire since being diagnosed with breast or gynecologic cancer?

We are conducting a study (Study ID: NRG-CC004) to see if using the oral medication, Bupropion, will improve sexual desire/motivation in women.

Study Facts

1. A decrease in sexual desire is common among women after diagnosis or treatment.
2. Participants will be randomized to 1 of 3 study drug groups including 2 doses of Bupropion or placebo.
3. The study will last approximately 10 weeks after beginning the study drug.
4. This study is voluntary and comes at no cost to participants.

In order to participate, you must:

- Be female
- Be at least 18 years of age
- Have a current or past diagnosis of breast or gynecologic cancer
- Be naturally or surgically post-menopausal
- Have completed all surgery, chemotherapy, and/or radiation at least 6 months ago
- Not be currently taking Tamoxifen or Bupropion
- Have experienced a decrease in sexual desire/motivation since diagnosis or treatment of cancer
- Be able to swallow whole capsules

Contact Information

For more information, please contact your doctor:

Name: Dr. William Fusselman (PCI Hematology & Oncology), or email his nurse
Email: catherine.fiala@unitypoint.org
Phone Number: 319- 369-7780

NRG ONCOLOGY
Advancing Research. Improving Lives.™

Update Date: 04/04/18

Protocol Version Date: 09/08/17